Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year AstraZeneca PLC grew revenues 3.29% from 44.35bn to 45.81bn while net income improved 81.11% from 3.29bn to 5.96bn.
Gross margin82.17%
Net profit margin13.31%
Operating margin18.40%
Return on assets6.37%
Return on equity17.29%
Return on investment8.73%
More ▼

Cash flow in USDView more

In 2023, cash reserves at AstraZeneca PLC fell by 346.00m. However, the company earned 10.35bn from its operations for a Cash Flow Margin of 22.58%. In addition the company used 4.06bn on investing activities and also paid 6.57bn in financing cash flows.
Cash flow per share5.78
Price/Cash flow per share21.29
Book value per share19.02
Tangible book value per share-10.85
More ▼

Balance sheet in USDView more

AstraZeneca PLC has a Debt to Total Capital ratio of 47.95%, a lower figure than the previous year's 77.25%.
Current ratio0.8856
Quick ratio0.7009
Total debt/total equity0.9227
Total debt/total capital0.4795
More ▼

Growth rates in USD

Growth rate information is not available.
Div yield(5 year avg)2.48%
Div growth rate (5 year)1.10%
Payout ratio (TTM)0.00%
EPS growth(5 years)17.52
EPS (TTM) vs
TTM 1 year ago
34.45
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.